Effect of astaxanthin administration for heart failure patients with left ventricular systolic dysfunction.

Effect of astaxanthin administration for heart failure patients with left ventricular systolic dysfunction. - Effect of astaxanthin administration for heart failure patients with left ventricular systolic dysfunction.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014088

Enrollment

Registered

2014-05-27

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure due to left ventricular systolic dysfunction

Interventions

Administration of astaxathin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) left ventricular ejection fraction <50% 2) NYHA functional class >= II 3) Ability to answer questionnaires by themselves

Exclusion criteria

Exclusion criteria: 1) Patients with organic valvular heart disease 2) Smokers 3) Patients under dialysis 4) Patients with chronic lung diseases 5) Patients with chronic inflammatory diseases 6) Patients with neoplasms 7) Patients who can not walk alone 8) Patients who were considered as ineligible by attending physicians

Design outcomes

Primary

Measure	Time frame
1) Changes in oxidative stress markers; 2) Changes in echocardiographic parameters; 3) Change in plasma B-type natriuretic peptide level; 4) Change in exercise tolerance; and 5) Changes in quality-of-life.	—

Secondary

Measure	Time frame
Correlations between primary outcomes and increase in plasma level of astaxanthin.	—

Countries

Japan

Contacts

Public ContactTakatoshi Kasai

Juntendo University Department of Cardiology

tkasai@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026